Which diphosphonate for routine bone scintigraphy (MDP, HDP or DPD)?

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmacy

Background:

• Bone scintigraphy is crucial for detecting metastatic cancer.
• Various diphosphonate agents, including MDP, HDP, and DPD, are used for bone imaging.
• Evaluating the comparative efficacy of these agents in routine clinical settings is important.

Purpose of the Study:

• To compare the diagnostic performance of MDP, HDP, and DPD in bone scintigraphy for cancer patients.
• To assess both qualitative and quantitative aspects of image analysis across different diphosphonate agents.

Main Methods:

• A study involving 772 cancer patients without selection criteria.
• Administration of three MDP kits, two HDP types, or DPD for bone scintigraphy.
• Evaluation of scintigrams based on qualitative criteria (image quality, contrast, uptake) and quantitative data (fixation ratios).

Main Results:

• No significant qualitative or quantitative advantages were found for HDP and DPD over MDP.
• Two MDP kits showed a slight superiority in detecting metastatic lesions compared to other agents.
• Quantitative data, including bone/soft tissue ratios, were similar across all diphosphonate types.

Conclusions:

• HDP and DPD do not offer decisive advantages over MDP in routine clinical bone scintigraphy.
• MDP remains a reliable agent, with some kits exhibiting slightly better metastatic lesion detectability.
• The choice of diphosphonate agent may not significantly impact diagnostic outcomes in unselected patient populations.